ArticleMolecules (Basel, Switzerland)2019
Efficacy of Obcordata A from
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Metabolic changes in kidney stone disease.Frontiers in immunology · 2023Pooled it
- Extracts ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Comparative Study of the Structural Characteristics and Bioactivity of Polysaccharides Extracted fromMolecules (Basel, Switzerland) · 2023Article
- Five New Polyoxypregnane Glycosides from the Vines ofMolecules (Basel, Switzerland) · 2022Article
- The complete chloroplast genome sequence ofMitochondrial DNA. Part B, Resources · 2022Article
- Discovery of Polyoxypregnane Derivatives FromFrontiers in chemistry · 2021Article
- Complete plastome sequence ofMitochondrial DNA. Part B, Resources · 2020Article
- Aspidoptoids A-D: Four New Diterpenoids fromMolecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Obcordata A (OA) is a polyoxypregnane glycoside derived from the Dai medicine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.